GlassScriptPhysician profile
David W Knorz
NPI 1235153917
$2,355.32
in general payments reported to CMS, 2019-2025
14 companies · $1,165 in 2025
The $1,165 reported for 2025 was more than what 95% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $210 · 2020: $49.95 · 2021: $213 · 2022: $184 · 2023: $149 · 2024: $384 · 2025: $1,165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,697.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $802.47 | 2019-2025 | Sapien 3 Ultra Resilia, Inspiris Resilia Aortic Valve, Konect Resilia |
| Becton, Dickinson and Company | $412.35 | 2025 | |
| Abiomed | $282.02 | 2022-2025 | Impella |
| Merck Sharp & Dohme LLC | $279.95 | 2019-2025 | Bridion |
| Teleflex LLC | $155.48 | 2022-2025 | Rusch, Arrow |
| Octapharma USA, INC. | $150.18 | 2025 | Fibryga |
| Chiesi USA, INC. | $85.75 | 2019-2021 | |
| Acelrx Pharmaceuticals, INC. | $50.09 | 2019-2021 | |
| Masimo Corporation | $42.18 | 2019-2021 | |
| Fisher & Paykel Healthcare INC | $24.13 | 2023 | Fisher & Paykel Healthcare |
| Abbott Laboratories | $23.58 | 2025 | Mitraclip |
| Pacira Pharmaceuticals Incorporated | $17.68 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $16.95 | 2023 | Andexxa |
| Werfen USA LLC | $12.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Knorz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.